Top

Published in:

01-02-2021 | Insulins | Review

The Roles of Insulin-Like Growth Factor Binding Protein Family in Development and Diseases

Authors: Fei Song, Xiao-Xia Zhou, Yu Hu, Gang Li, Yan Wang

Published in: Advances in Therapy | Issue 2/2021

Abstract

The insulin-like growth factor (IGF) system comprises ligands of IGF-I/II, IGF receptors (IGFR), IGF binding proteins (IGFBPs), and IGFBP hydrolases. The IGF system plays multiple roles during various disease development as IGFs are widely involved in cell proliferation and differentiation through regulating DNA transcription. Meanwhile, IGFBPs, which are mainly synthesized in the liver, can bind to IGFs and perform two different functions: either inhibition of IGFs by forming inactive compounds with IGF or enhancement of the function of IGFs by strengthening the IGF–IGFR interaction. Interestingly, IGFBPs may have wider functions through IGF-independent mechanisms. Studies have shown that IGFBPs play important roles in cardiovascular disease, tumor progression, fetal growth, and neuro-nutrition. In this review, we emphasize that different IGFBP family members have common or unique functions in numerous diseases; moreover, IGFBPs may serve as biomarkers for disease diagnosis and prediction.

Clemmons DR. Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev. 1997;8:45–62. https://doi.org/10.1016/s1359-6101(96)00053-6.

Lee PD, Giudice LC, Conover CA, Powell DR. Insulin-like growth factor binding protein-1: recent findings and new directions. Proc Soc Exp Biol Med. 1997;216:319–57. https://doi.org/10.3181/00379727-216-44182.CrossRefPubMed

Chicharro JL, Lopez-Calderon A, Hoyos J, et al. Effects of an endurance cycling competition on resting serum insulin-like growth factor I (IGF-I) and its binding proteins IGFBP-1 and IGFBP-3. Br J Sports Med. 2001;35:303–7. https://doi.org/10.1136/bjsm.35.5.303.CrossRefPubMedPubMedCentral

van Doorn J. Insulin-like growth factor-II and bioactive proteins containing a part of the E-domain of pro-insulin-like growth factor-II. BioFactors. 2020;46:563–78. https://doi.org/10.1002/biof.1623.

Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4:505–18. https://doi.org/10.1038/nrc1387.CrossRefPubMed

Neirijnck Y, Papaioannou MD, Nef S. The insulin/IGF system in mammalian sexual development and reproduction. Int J Mol Sci. 2019;20. https://doi.org/10.3390/ijms20184440.

Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer. 2003;107:873–7. https://doi.org/10.1002/ijc.11487.CrossRefPubMed

Clemmons DR, Busby WH, Arai T, et al. Role of insulin-like growth factor binding proteins in the control of IGF actions. Prog Growth Factor Res. 1995;6:357–66. https://doi.org/10.1016/0955-2235(95)00013-5.CrossRefPubMed

Ekstrom K, Salemyr J, Zachrisson I, Carlsson-Skwirut C, Ortqvist E, Bang P. Normalization of the IGF-IGFBP axis by sustained nightly insulinization in type 1 diabetes. Diabetes Care. 2007;30:1357–63. https://doi.org/10.2337/dc06-2328.CrossRefPubMed

10.

Rowlands MA, Holly JMP, Gunnell D, et al. Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT. Cancer Res. 2012;72:503–515. https://doi.org/10.1158/0008-5472.Can-11-1601.

11.

Kiepe D, Ulinski T, Powell DR, Durham SK, Mehls O, Tönshoff B. Differential effects of insulin-like growth factor binding proteins-1, -2, -3, and -6 on cultured growth plate chondrocytes. Kidney Int. 2002;62:1591–600. https://doi.org/10.1046/j.1523-1755.2002.00603.x.CrossRefPubMed

12.

Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocrine Rev. 1999;20:761–87. https://doi.org/10.1210/edrv.20.6.0382.CrossRef

13.

Wheatcroft SB, Kearney MT. IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: implications for metabolic homeostasis. Trends Endocrinol Metabol. 2009;20:153–62. https://doi.org/10.1016/j.tem.2009.01.002.CrossRef

14.

Wallander M, Norhammar A, Malmberg K, Ohrvik J, Rydén L, Brismar K. IGF binding protein 1 predicts cardiovascular morbidity and mortality in patients with acute myocardial infarction and type 2 diabetes. Diabetes Care. 2007;30:2343–8. https://doi.org/10.2337/dc07-0825.CrossRefPubMed

15.

Ekström K, Salemyr J, Zachrisson I, Carlsson-Skwirut C, Ortqvist E, Bang P. Normalization of the IGF-IGFBP axis by sustained nightly insulinization in type 1 diabetes. Diabetes Care. 2007;30:1357–63. https://doi.org/10.2337/dc06-2328.CrossRefPubMed

16.

Ramirez VI, Miller E, Meireles CL, Gelfond J, Krummel DA, Powell TL. Adiponectin and IGFBP-1 in the development of gestational diabetes in obese mothers. BMJ Open Diabetes Res Care. 2014;2:e000010. https://doi.org/10.1136/bmjdrc-2013-000010.CrossRefPubMedPubMedCentral

17.

Song Z, Dai X, Yu H, Luo Q, Zhang H, Wu L. Increased serum IGFBP-1 and reduced insulin resistance after Roux-en-Y gastric bypass in Chinese patients with type 2 diabetes: a 6-month follow-up. Obesity Surg. 2018;28:3165–71. https://doi.org/10.1007/s11695-018-3242-8.CrossRef

18.

Leinonen ES, Salonen JT, Salonen RM, et al. Reduced IGFBP-1 is associated with thickening of the carotid wall in type 2 diabetes. Diabetes Care. 2002;25:1807–12. https://doi.org/10.2337/diacare.25.10.1807.CrossRefPubMed

19.

Chicharro JL, López-Calderon A, Hoyos J, et al. Effects of an endurance cycling competition on resting serum insulin-like growth factor I (IGF-I) and its binding proteins IGFBP-1 and IGFBP-3. Br J Sports Med. 2001;35:303–7. https://doi.org/10.1136/bjsm.35.5.303.CrossRefPubMedPubMedCentral

20.

Stilling F, Wallenius S, Michaëlsson K, Dalgård C, Brismar K, Wolk A. High insulin-like growth factor-binding protein-1 (IGFBP-1) is associated with low relative muscle mass in older women. Metab Clin Exp. 2017;73:36–42. https://doi.org/10.1016/j.metabol.2017.04.013.CrossRefPubMed

21.

Gupta MB, Abu Shehab M, Nygard K, et al. IUGR is associated with marked hyperphosphorylation of decidual and maternal plasma IGFBP-1. J Clin Endocrinol Metab. 2019;104:408–22. https://doi.org/10.1210/jc.2018-00820.CrossRefPubMed

22.

Shehab MA, Biggar K, Singal SS, et al. Exposure of decidualized HIESC to low oxygen tension and leucine deprivation results in increased IGFBP-1 phosphorylation and reduced IGF-I bioactivity. Mol Cell Endocrinol. 2017;452:1–14. https://doi.org/10.1016/j.mce.2017.04.005.CrossRefPubMedPubMedCentral

23.

Qiao L, Wattez JS, Lee S, et al. Knockout maternal adiponectin increases fetal growth in mice: potential role for trophoblast IGFBP-1. Diabetologia. 2016;59:2417–25. https://doi.org/10.1007/s00125-016-4061-x.CrossRefPubMedPubMedCentral

24.

Xu YW, Chen H, Hong CQ, et al. Serum IGFBP-1 as a potential biomarker for diagnosis of early-stage upper gastrointestinal tumour. EBioMedicine. 2020;51:102566. https://doi.org/10.1016/j.ebiom.2019.11.027.CrossRefPubMedPubMedCentral

25.

Yau SW, Azar WJ, Sabin MA, Werther GA, Russo VC. IGFBP-2 - taking the lead in growth, metabolism and cancer. J Cell Commun Signal. 2015;9:125–42. https://doi.org/10.1007/s12079-015-0261-2.CrossRefPubMedPubMedCentral

26.

Xi G, Wai C, Rosen CJ, Clemmons DR. A peptide containing the receptor binding site of insulin-like growth factor binding protein-2 enhances bone mass in ovariectomized rats. Bone Res. 2018;6:23. https://doi.org/10.1038/s41413-018-0024-9.CrossRefPubMedPubMedCentral

27.

Carter S, Lemieux I, Li Z, et al. Changes in IGFBP-2 levels following a one-year lifestyle modification program are independently related to improvements in plasma apo B and LDL apo B levels. Atherosclerosis. 2019;281:89–97. https://doi.org/10.1016/j.atherosclerosis.2018.12.016.CrossRefPubMed

28.

Wittenbecher C, Ouni M, Kuxhaus O, et al. Insulin-like growth factor binding protein 2 (IGFBP-2) and the risk of developing type 2 diabetes. Diabetes. 2019;68:188–97. https://doi.org/10.2337/db18-0620.CrossRefPubMed

29.

Khan S. IGFBP-2 signaling in the brain: from brain development to higher order brain functions. Front Endocrinol. 2019;10:822. https://doi.org/10.3389/fendo.2019.00822.CrossRef

30.

McGrath ER, Himali JJ, Levy D, et al. Circulating IGFBP-2: a novel biomarker for incident dementia. Ann Clin Transl Neurol. 2019;6:1659–70. https://doi.org/10.1002/acn3.50854.CrossRefPubMedPubMedCentral

31.

Han S, Li Z, Master LM, Master ZW, Wu A. Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathway. Br J Cancer. 2014;111:1400–9. https://doi.org/10.1038/bjc.2014.435.CrossRefPubMedPubMedCentral

32.

Lin Y, Jiang T, Zhou K, et al. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro Oncol. 2009;11:468–76. https://doi.org/10.1215/15228517-2008-114.CrossRefPubMedPubMedCentral

33.

Muessig JM, Lichtenauer M, Wernly B, et al. Insulin like growth factor binding protein 2 (IGFBP-2) for risk prediction in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI). Int J Cardiol. 2019;277:54–9. https://doi.org/10.1016/j.ijcard.2018.09.091.CrossRefPubMed

34.

van den Beld AW, Carlson OD, Doyle ME, et al. IGFBP-2 and aging: a 20-year longitudinal study on IGFBP-2, IGF-I, BMI, insulin sensitivity and mortality in an aging population. Eur J Endocrinol. 2019;180:109–16. https://doi.org/10.1530/eje-18-0422.CrossRefPubMedPubMedCentral

35.

Shen X, Xi G, Maile LA, Wai C, Rosen CJ, Clemmons DR. Insulin-like growth factor (IGF) binding protein 2 functions coordinately with receptor protein tyrosine phosphatase beta and the IGF-I receptor to regulate IGF-I-stimulated signaling. Mol Cell Biol. 2012;32:4116–30. https://doi.org/10.1128/MCB.01011-12.CrossRefPubMedPubMedCentral

36.

Xi G, Demambro VE, D'Costa S, et al. Estrogen stimulation of pleiotrophin enhances osteoblast differentiation and maintains bone mass in IGFBP-2 null mice. Endocrinology. 2020;161:bqz007. https://doi.org/10.1210/endocr/bqz007.CrossRefPubMed

37.

Xi G, Wai C, DeMambro V, Rosen CJ, Clemmons DR. IGFBP-2 directly stimulates osteoblast differentiation. J Bone Miner Res. 2014;29:2427–38. https://doi.org/10.1002/jbmr.2282.CrossRefPubMedPubMedCentral

38.

Xi G, Shen X, Rosen CJ, Clemmons DR. IRS-1 functions as a molecular scaffold to coordinate IGF-I/IGFBP-2 signaling during osteoblast differentiation. J Bone Miner Res. 2016;31:1300–14. https://doi.org/10.1002/jbmr.2791.CrossRefPubMedPubMedCentral

39.

Xi G, D'Costa S, Wai C, Xia SK, Cox ZC, Clemmons DR. IGFBP-2 stimulates calcium/calmodulin-dependent protein kinase kinase 2 activation leading to AMP-activated protein kinase induction which is required for osteoblast differentiation. J Cell Physiol. 2019;234:23232–42. https://doi.org/10.1002/jcp.28890.CrossRefPubMed

40.

Ho GYF, Zheng SL, Cushman M, et al. Associations of insulin and IGFBP-3 with lung cancer susceptibility in current smokers. J Natl Cancer Inst. 2016;108:djw012. https://doi.org/10.1093/jnci/djw012.CrossRefPubMedCentral

41.

Kim JH, Choi DS, Lee OH, Oh SH, Lippman SM, Lee HY. Antiangiogenic antitumor activities of IGFBP-3 are mediated by IGF-independent suppression of Erk1/2 activation and Egr-1-mediated transcriptional events. Blood. 2011;118:2622–31. https://doi.org/10.1182/blood-2010-08-299784.CrossRefPubMedPubMedCentral

42.

Qiu N, He YF, Zhang SM, et al. Cullin7 enhances resistance to trastuzumab therapy in Her2 positive breast cancer via degrading IRS-1 and downregulating IGFBP-3 to activate the PI3K/AKT pathway. Cancer Lett. 2019;464:25–36. https://doi.org/10.1016/j.canlet.2019.08.008.CrossRefPubMed

43.

Fu T, Pappou EP, Guzzetta AA, et al. IGFBP-3 gene methylation in primary tumor predicts recurrence of stage II colorectal cancers. Ann Surg. 2016;263:337–44. https://doi.org/10.1097/sla.0000000000001204.CrossRefPubMedPubMedCentral

44.

Ho L, Stojanovski A, Whetstone H, et al. Gli2 and p53 cooperate to regulate IGFBP-3- mediated chondrocyte apoptosis in the progression from benign to malignant cartilage tumors. Cancer Cell. 2009;16:126–36. https://doi.org/10.1016/j.ccr.2009.05.013.CrossRefPubMed

45.

Tan VY, Biernacka KM, Dudding T, et al. Reassessing the association between circulating vitamin D and IGFBP-3: observational and mendelian randomization estimates from independent sources. Cancer Epidemiol Biomark Prevent. 2018;27:1462–71. https://doi.org/10.1158/1055-9965.Epi-18-0113.CrossRef

46.

Scully T, Scott CD, Firth SM, et al. Enhancement of mammary tumour growth by IGFBP-3 involves impaired T cell accumulation. Endocrine Relat Cancer. 2018;25:111–22. https://doi.org/10.1530/erc-17-0384.CrossRef

47.

de Silva HC, Lin MZ, Phillips L, Martin JL, Baxter RC. IGFBP-3 interacts with NONO and SFPQ in PARP-dependent DNA damage repair in triple-negative breast cancer. Cell Mol Life Sci. 2019;76:2015–30. https://doi.org/10.1007/s00018-019-03033-4.CrossRefPubMed

48.

Sakata J, Hirosue A, Yoshida R, et al. Enhanced expression of IGFBP-3 reduces radiosensitivity and is associated with poor prognosis in oral squamous cell carcinoma. Cancers (Basel). 2020;12:494. https://doi.org/10.3390/cancers12020494.CrossRefPubMedCentral

49.

Elloumi M, El Elj N, Zaouali M, et al. IGFBP-3, a sensitive marker of physical training and overtraining. Br J Sports Med. 2005;39:604–10. https://doi.org/10.1136/bjsm.2004.014183.CrossRefPubMedPubMedCentral

50.

Huang XY, Huang ZL, Yang JH, et al. Pancreatic cancer cell-derived IGFBP-3 contributes to muscle wasting. J Exp Clin Cancer Res. 2016;35:46. https://doi.org/10.1186/s13046-016-0317-z.CrossRefPubMedPubMedCentral

51.

He YH, Lu X, Yang LQ, Xu LY, Kong QP. Association of the insulin-like growth factor binding protein 3 (IGFBP-3) polymorphism with longevity in Chinese nonagenarians and centenarians. Aging. 2014;6:944–56. https://doi.org/10.18632/aging.100703.CrossRef

52.

Teumer A, Qi Q, Nethander M, et al. Genomewide meta-analysis identifies loci associated with IGF-I and IGFBP-3 levels with impact on age-related traits. Aging Cell. 2016;15:811–24. https://doi.org/10.1111/acel.12490.CrossRefPubMedPubMedCentral

53.

Hong S, Kim MM. IGFBP-3 plays an important role in senescence as an aging marker. Environ Toxicol Pharmacol. 2018;59:138–45. https://doi.org/10.1016/j.etap.2018.03.014.CrossRefPubMed

54.

Liu L, Jiang Y, Steinle JJ. Glycyrrhizin protects IGFBP-3 knockout mice from retinal damage. Cytokine. 2020;125:154856. https://doi.org/10.1016/j.cyto.2019.154856.CrossRefPubMed

55.

Titone R, Zhu M, Robertson DM. Mutual regulation between IGF-1R and IGFBP-3 in human corneal epithelial cells. J Cell Physiol. 2019;234:1426–41. https://doi.org/10.1002/jcp.26948.CrossRefPubMed

56.

Busch M, Krüger A, Gross S, et al. Relation of IGF-1 and IGFBP-3 with prevalent and incident atrial fibrillation in a population-based study. Heart Rhythm. 2019;16:1314–9. https://doi.org/10.1016/j.hrthm.2019.03.017.CrossRefPubMed

57.

Zhu W, Shiojima I, Ito Y, et al. IGFBP-4 is an inhibitor of canonical Wnt signalling required for cardiogenesis. Nature. 2008;454:345–9. https://doi.org/10.1038/nature07027.CrossRefPubMed

58.

Konev AA, Kharitonov AV, Rozov FN, et al. CT-IGFBP-4 as a novel prognostic biomarker in acute heart failure. ESC Heart Fail. 2020;. https://doi.org/10.1002/ehf2.12590.CrossRefPubMedPubMedCentral

59.

Cediel G, Rueda F, Oxvig C, et al. Prognostic value of the Stanniocalcin-2/PAPP-A/IGFBP-4 axis in ST-segment elevation myocardial infarction. Cardiovasc Diabetol. 2018;17:63. https://doi.org/10.1186/s12933-018-0710-3.CrossRefPubMedPubMedCentral

60.

Hjortebjerg R, Tarnow L, Jorsal A, et al. IGFBP-4 Fragments as markers of cardiovascular mortality in type 1 diabetes patients with and without nephropathy. J Clin Endocrinol Metab. 2015;100:3032–40. https://doi.org/10.1210/jc.2015-2196.CrossRefPubMed

61.

Son JW, Park J, Kim YE, et al. Glia-like cells from late-passage human MSCs protect against ischemic stroke through IGFBP-4. Mol Neurobiol. 2019;56:7617–30. https://doi.org/10.1007/s12035-019-1629-8.CrossRefPubMed

62.

Mense K, Heidekorn-Dettmer J, Wirthgen E, et al. Increased concentrations of insulin-like growth factor binding protein (IGFBP)-2, IGFBP-3, and IGFBP-4 are associated with fetal mortality in pregnant cows. Front Endocrinol (Lausanne). 2018;9:310. https://doi.org/10.3389/fendo.2018.00310.CrossRef

63.

Contois LW, Akalu A, Caron JM, et al. Inhibition of tumor-associated αvβ3 integrin regulates the angiogenic switch by enhancing expression of IGFBP-4 leading to reduced melanoma growth and angiogenesis in vivo. Angiogenesis. 2015;18:31–46. https://doi.org/10.1007/s10456-014-9445-2.CrossRefPubMed

64.

Kalus W, Zweckstetter M, Renner C, et al. Structure of the IGF-binding domain of the insulin-like growth factor-binding protein-5 (IGFBP-5): implications for IGF and IGF-I receptor interactions. EMBO J. 1998;17:6558–72. https://doi.org/10.1093/emboj/17.22.6558.CrossRefPubMedPubMedCentral

65.

Salih DA, Tripathi G, Holding C, et al. Insulin-like growth factor-binding protein 5 (Igfbp5) compromises survival, growth, muscle development, and fertility in mice. Proc Natl Acad Sci U S A. 2004;101:4314–9. https://doi.org/10.1073/pnas.0400230101.CrossRefPubMedPubMedCentral

66.

DiPrisco B, Kumar A, Kalra B, et al. Placental proteases PAPP-A and PAPP-A2, the binding proteins they cleave (IGFBP-4 and -5), and IGF-I and IGF-II: levels in umbilical cord blood and associations with birth weight and length. Metabol Clin Exp. 2019;100:153959. https://doi.org/10.1016/j.metabol.2019.153959.CrossRef

67.

Wang Y, Jia Z, Diao S, et al. IGFBP5 enhances osteogenic differentiation potential of periodontal ligament stem cells and Wharton’s jelly umbilical cord stem cells, via the JNK and MEK/Erk signalling pathways. Cell Prolif. 2016;49:618–27. https://doi.org/10.1111/cpr.12284.CrossRefPubMedPubMedCentral

68.

Ren H, Yin P, Duan C. IGFBP-5 regulates muscle cell differentiation by binding to IGF-II and switching on the IGF-II auto-regulation loop. J Cell Biol. 2008;182:979–91. https://doi.org/10.1083/jcb.200712110.CrossRefPubMedPubMedCentral

69.

Lin SC, Wang CP, Chen YM, et al. Regulation of IGFBP-5 expression during tumourigenesis and differentiation of oral keratinocytes. J Pathol. 2002;198:317–25. https://doi.org/10.1002/path.1220.CrossRefPubMed

70.

Luther GA, Lamplot J, Chen X, et al. IGFBP5 domains exert distinct inhibitory effects on the tumorigenicity and metastasis of human osteosarcoma. Cancer Lett. 2013;336:222–30. https://doi.org/10.1016/j.canlet.2013.05.002.CrossRefPubMedPubMedCentral

71.

Dong C, Zhang J, Fang S, Liu F. IGFBP5 increases cell invasion and inhibits cell proliferation by EMT and Akt signaling pathway in glioblastoma multiforme cells. Cell Div. 2020;15:4. https://doi.org/10.1186/s13008-020-00061-6.CrossRefPubMedPubMedCentral

72.

Sureshbabu A, Okajima H, Yamanaka D, et al. IGFBP5 induces cell adhesion, increases cell survival and inhibits cell migration in MCF-7 human breast cancer cells. J Cell Sci. 2012;125:1693–705. https://doi.org/10.1242/jcs.092882.CrossRefPubMed

73.

Nguyen XX, Muhammad L, Nietert PJ, Feghali-Bostwick C. IGFBP-5 promotes fibrosis via increasing its own expression and that of other pro-fibrotic mediators. Front Endocrinol. 2018;9:601. https://doi.org/10.3389/fendo.2018.00601.CrossRef

74.

Song SE, Kim YW, Kim JY, Lee DH, Kim JR, Park SY. IGFBP5 mediates high glucose-induced cardiac fibroblast activation. J Mol Endocrinol. 2013;50:291–303. https://doi.org/10.1530/JME-12-0194.CrossRefPubMed

75.

Sanada F, Taniyama Y, Muratsu J, et al. Activated factor X induces endothelial cell senescence through IGFBP-5. Sci Rep. 2016;6:35580. https://doi.org/10.1038/srep35580.CrossRefPubMedPubMedCentral

76.

Capuano AW, Wilson RS, Honer WG, et al. Brain IGFBP-5 modifies the relation of depressive symptoms to decline in cognition in older persons. J Affect Disord. 2019;250:313–8. https://doi.org/10.1016/j.jad.2019.03.051.CrossRefPubMedPubMedCentral

77.

Simon CM, Rauskolb S, Gunnersen JM, et al. Dysregulated IGFBP5 expression causes axon degeneration and motoneuron loss in diabetic neuropathy. Acta Neuropathol. 2015;130:373–87. https://doi.org/10.1007/s00401-015-1446-8.CrossRefPubMedPubMedCentral

78.

Bach LA. Current ideas on the biology of IGFBP-6: more than an IGF-II inhibitor? Growth Horm IGF Res. 2016;30–31:81–6. https://doi.org/10.1016/j.ghir.2016.09.004.CrossRefPubMed

79.

Iosef C, Vilk G, Gkourasas T, et al. Insulin-like growth factor binding protein-6 (IGFBP-6) interacts with DNA-end binding protein Ku80 to regulate cell fate. Cell Signal. 2010;22:1033–43. https://doi.org/10.1016/j.cellsig.2010.02.006.CrossRefPubMed

80.

Qiu F, Gao W, Wang B. Correlation of IGFBP-6 expression with apoptosis and migration of colorectal carcinoma cells. Cancer Biomark. 2018;21:893–8. https://doi.org/10.3233/CBM-170947.CrossRefPubMed

81.

Yang Z, Bach LA. Differential effects of insulin-like growth factor binding protein-6 (IGFBP-6) on migration of two ovarian cancer cell lines. Front Endocrinol (Lausanne). 2014;5:231. https://doi.org/10.3389/fendo.2014.00231.CrossRef

82.

Oliva CR, Halloran B, Hjelmeland AB, et al. IGFBP6 controls the expansion of chemoresistant glioblastoma through paracrine IGF2/IGF-1R signaling. Cell Commun Signal. 2018;16:61. https://doi.org/10.1186/s12964-018-0273-7.CrossRefPubMedPubMedCentral

83.

Bei Y, Huang Q, Shen J, et al. IGFBP6 regulates cell apoptosis and migration in glioma. Cell Mol Neurobiol. 2017;37:889–98. https://doi.org/10.1007/s10571-016-0426-4.CrossRefPubMed

84.

Fu P, Yang Z, Bach LA. Prohibitin-2 binding modulates insulin-like growth factor-binding protein-6 (IGFBP-6)-induced rhabdomyosarcoma cell migration. J Biol Chem. 2013;288:29890–900. https://doi.org/10.1074/jbc.M113.510826.CrossRefPubMedPubMedCentral

85.

Zhao HM, Sheng MJ, Yu J. Expression of IGFBP-6 in a proliferative vitreoretinopathy rat model and its effects on retinal pigment epithelial cell proliferation and migration. Int J Ophthalmol. 2014;7:27–33. https://doi.org/10.3980/j.issn.2222-3959.2014.01.05.CrossRefPubMedPubMedCentral

86.

Wang S, Liu Y, Wu C, et al. The expression of IGFBP6 after spinal cord injury: implications for neuronal apoptosis. Neurochem Res. 2017;42:455–67. https://doi.org/10.1007/s11064-016-2092-9.CrossRefPubMed

87.

Conese M, D'Oria S, Castellani S, Trotta R, Montemurro P, Liso A. Insulin-like growth factor-6 (IGFBP-6) stimulates neutrophil oxidative burst, degranulation and chemotaxis. Inflamm Res. 2018;67:107–9. https://doi.org/10.1007/s00011-017-1107-6.CrossRefPubMed

88.

Akiel M, Guo C, Li X, et al. IGFBP7 deletion promotes hepatocellular carcinoma. Cancer Res. 2017;77:4014–25. https://doi.org/10.1158/0008-5472.CAN-16-2885.CrossRefPubMedPubMedCentral

89.

Chen D, Siddiq A, Emdad L, et al. Corrigendum to “Insulin-like growth factor-binding protein-7 (IGFBP7): a promising gene therapeutic for hepatocellular carcinoma (HCC)”. Mol Ther. 2015;23:1278. https://doi.org/10.1038/mt.2015.57.

90.

Chen Y, Cui T, Knosel T, Yang L, Zoller K, Petersen I. IGFBP7 is a p53 target gene inactivated in human lung cancer by DNA hypermethylation. Lung Cancer. 2011;73:38–44. https://doi.org/10.1016/j.lungcan.2010.10.015.CrossRefPubMed

91.

Benatar T, Yang W, Amemiya Y, et al. IGFBP7 reduces breast tumor growth by induction of senescence and apoptosis pathways. Breast Cancer Res Treat. 2012;133:563–73. https://doi.org/10.1007/s10549-011-1816-4.CrossRefPubMed

92.

Li N, Han J, Tang J, Ying Y. IGFBP-7 inhibits the differentiation of oligodendrocyte precursor cells via regulation of Wnt/β-catenin signaling. J Cell Biochem. 2018;119:4742–50. https://doi.org/10.1002/jcb.26654.CrossRefPubMed

93.

Bolomsky A, Hose D, Schreder M, et al. Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma. J Hematol Oncol. 2015;8:10. https://doi.org/10.1186/s13045-014-0105-1.CrossRefPubMedPubMedCentral

94.

An W, Ben QW, Chen HT, et al. Low expression of IGFBP7 is associated with poor outcome of pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2012;19:3971–8. https://doi.org/10.1245/s10434-012-2407-2.CrossRefPubMed

95.

Aregger F, Uehlinger DE, Witowski J, et al. Identification of IGFBP-7 by urinary proteomics as a novel prognostic marker in early acute kidney injury. Kidney Int. 2014;85:909–19. https://doi.org/10.1038/ki.2013.363.CrossRefPubMed

96.

Bai Z, Fang F, Xu Z, et al. Serum and urine FGF23 and IGFBP-7 for the prediction of acute kidney injury in critically ill children. BMC Pediatr. 2018;18:192. https://doi.org/10.1186/s12887-018-1175-y.CrossRefPubMedPubMedCentral

97.

Wetz AJ, Richardt EM, Wand S, et al. Quantification of urinary TIMP-2 and IGFBP-7: an adequate diagnostic test to predict acute kidney injury after cardiac surgery? Crit Care. 2015;19:3. https://doi.org/10.1186/s13054-014-0717-4.CrossRefPubMedPubMedCentral

98.

Gu HF, Gu T, Hilding A, et al. Evaluation of IGFBP-7 DNA methylation changes and serum protein variation in Swedish subjects with and without type 2 diabetes. Clin Epigenet. 2013;5:20. https://doi.org/10.1186/1868-7083-5-20.CrossRef

Title: The Roles of Insulin-Like Growth Factor Binding Protein Family in Development and Diseases
Authors: Fei Song
Xiao-Xia Zhou
Yu Hu
Gang Li
Yan Wang
Publication date: 01-02-2021
Publisher: Springer Healthcare
Keywords: Insulins
Insulins
Published in: Advances in Therapy / Issue 2/2021
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI: https://doi.org/10.1007/s12325-020-01581-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2021

Vardenafil in the Treatment of Male Erectile Dysfunction: A Systematic Review and Meta-Analysis

Pharmacokinetic Interaction Between Telmisartan and Rosuvastatin/Ezetimibe After Multiple Oral Administration in Healthy Subjects

The Prevalence of Overactive Bladder Symptoms in Women in Algeria, Egypt, Jordan and Lebanon: A Cross-Sectional Population-Based Survey

Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison

Costs and Healthcare Resource Use Associated with Risk of Cardiovascular Morbidity in Patients with Chronic Kidney Disease: Evidence from a Systematic Literature Review

Naltrexone’s Impact on Cancer Progression and Mortality: A Systematic Review of Studies in Humans, Animal Models, and Cell Cultures

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage